Does Dr. DONALD HILLEBRAND have financial conflicts of interest?

Dr. DONALD HILLEBRAND (MD) has received a total of $122,901 in pharmaceutical and medical device industry funding between 2021 and 2025. This includes $122,901 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. DONALD HILLEBRAND?

According to CMS Open Payments data, Dr. DONALD HILLEBRAND received funding from INTERCEPT PHARMACEUTICALS ($34,232), GILEAD SCIENCES ($29,254), and ABBVIE ($24,006).

Does Dr. DONALD HILLEBRAND receive research grants or speaking fees?

Dr. DONALD HILLEBRAND has received $122,901 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. DONALD HILLEBRAND

MDReal-Time Hydrated

Specialty: Internal Medicine, Transplant Hepatology

Practice Location: KANSAS CITY, MO 64111

NPI Number: 1770561946

LIFETIME INDUSTRY VALUE

$122,901

2021 – 2025 Cumulative

Conflict of Interest Analysis

Dr. HILLEBRAND is a verified Internal Medicine, Transplant Hepatology practitioner based in KANSAS CITY, MO.

Between 2021 and 2025, Dr. HILLEBRAND had an overall industry promotional and research financial footprint of $122,901 as recorded in the federal CMS Open Payments database.

$122,901 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. HILLEBRAND's primary funding source is INTERCEPT PHARMACEUTICALS, which accounts for $34,232 (representing 27.9% of overall industry footprint).

Data coverage: 2021 – 2025 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

INTERCEPT PHARMACEUTICALS

Rank 1

$34,232

27.9%

GILEAD SCIENCES

Rank 2

$29,254

23.8%

ABBVIE

Rank 3

$24,006

19.5%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2025

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.